Tags

Type your tag names separated by a space and hit enter

Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine.
Hum Vaccin Immunother. 2015; 11(12):2839-48.HV

Abstract

During the past decade, a number of H5 subtype influenza vaccines have been developed and tested in clinical trials, but most of them induced poor serum antibody responses prompting the evaluation of novel vaccination approaches. One of the most promising ones is a "prime-boost" strategy, which could result in the induction of prompt and robust immune responses to a booster influenza vaccine following priming with homologous or heterologous vaccine strains. In our study we evaluated immunogenicity of an adjuvanted A(H5N1) inactivated influenza vaccine (IIV) in healthy adult subjects who received A(H5N2) live attenuated influenza vaccine (LAIV) 1.5 years earlier and compared this with a group of naïve subjects. We found that priming with A(H5N2) LAIV induced a long-lasting B-cell immunological memory against influenza A(H5N1) virus, which was brought on by more prompt and vigorous antibody production to a single dose of A(H5N1) IIV in the primed group, compared to the naïve controls. Thus, by day 28 after the first booster dose, the hemagglutination inhibition and neutralizing (MN) antibody titer rises were 17.2 and 30.8 in the primed group, compared to 2.3 and 8.0 in the control group, respectively. The majority (79%) of the primed individuals achieved seroprotective MN antibody titers at 7 days after the first dose of the IIV. All LAIV-primed volunteers had MN titers ≥ 1:40 by Day 28 after one dose of IIV, whereas only 58% subjects from the naïve control group developed similar immune responses at this time point. The second A(H5N1) IIV dose did not increase the immune response in the LAIV-primed group, whereas 2 doses of IIV were required for naïve volunteers to develop significant immune responses. These findings were of special significance since Russian-based LAIV technology has been licensed to WHO, through whom the vaccine has been provided to vaccine manufacturers in India, China and Thailand - countries particularly vulnerable to a pandemic influenza. The results of our study will be useful to inform the development of vaccination strategies in these countries in the event of a pandemic.

Authors+Show Affiliations

a Institute of Experimental Medicine ; Saint Petersburg , Russia.a Institute of Experimental Medicine ; Saint Petersburg , Russia.a Institute of Experimental Medicine ; Saint Petersburg , Russia.a Institute of Experimental Medicine ; Saint Petersburg , Russia.a Institute of Experimental Medicine ; Saint Petersburg , Russia.a Institute of Experimental Medicine ; Saint Petersburg , Russia.a Institute of Experimental Medicine ; Saint Petersburg , Russia.b Research Institute of Influenza ; Saint Petersburg , Russia.b Research Institute of Influenza ; Saint Petersburg , Russia.c Department of Preclinical Trials, Microge ; Moscow , Russia.d PATH ; Seattle , WA USA.a Institute of Experimental Medicine ; Saint Petersburg , Russia. d PATH ; Seattle , WA USA.

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26697973

Citation

Rudenko, Larisa, et al. "Assessment of Immune Responses to H5N1 Inactivated Influenza Vaccine Among Individuals Previously Primed With H5N2 Live Attenuated Influenza Vaccine." Human Vaccines & Immunotherapeutics, vol. 11, no. 12, 2015, pp. 2839-48.
Rudenko L, Naykhin A, Donina S, et al. Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine. Hum Vaccin Immunother. 2015;11(12):2839-48.
Rudenko, L., Naykhin, A., Donina, S., Korenkov, D., Petukhova, G., Isakova-Sivak, I., Losev, I., Stukova, M., Erofeeva, M., Nikiforova, A., Power, M., & Flores, J. (2015). Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine. Human Vaccines & Immunotherapeutics, 11(12), 2839-48. https://doi.org/10.1080/21645515.2015.1069931
Rudenko L, et al. Assessment of Immune Responses to H5N1 Inactivated Influenza Vaccine Among Individuals Previously Primed With H5N2 Live Attenuated Influenza Vaccine. Hum Vaccin Immunother. 2015;11(12):2839-48. PubMed PMID: 26697973.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine. AU - Rudenko,Larisa, AU - Naykhin,Anatoly, AU - Donina,Svetlana, AU - Korenkov,Daniil, AU - Petukhova,Galina, AU - Isakova-Sivak,Irina, AU - Losev,Igor, AU - Stukova,Marina, AU - Erofeeva,Mariana, AU - Nikiforova,Alexandra, AU - Power,Maureen, AU - Flores,Jorge, PY - 2015/12/25/entrez PY - 2015/12/25/pubmed PY - 2016/9/27/medline KW - H5 avian influenza viruses KW - clinical trial KW - inactivated influenza vaccine KW - live attenuated influenza vaccine KW - memory immune response KW - prime-boost strategy KW - safety SP - 2839 EP - 48 JF - Human vaccines & immunotherapeutics JO - Hum Vaccin Immunother VL - 11 IS - 12 N2 - During the past decade, a number of H5 subtype influenza vaccines have been developed and tested in clinical trials, but most of them induced poor serum antibody responses prompting the evaluation of novel vaccination approaches. One of the most promising ones is a "prime-boost" strategy, which could result in the induction of prompt and robust immune responses to a booster influenza vaccine following priming with homologous or heterologous vaccine strains. In our study we evaluated immunogenicity of an adjuvanted A(H5N1) inactivated influenza vaccine (IIV) in healthy adult subjects who received A(H5N2) live attenuated influenza vaccine (LAIV) 1.5 years earlier and compared this with a group of naïve subjects. We found that priming with A(H5N2) LAIV induced a long-lasting B-cell immunological memory against influenza A(H5N1) virus, which was brought on by more prompt and vigorous antibody production to a single dose of A(H5N1) IIV in the primed group, compared to the naïve controls. Thus, by day 28 after the first booster dose, the hemagglutination inhibition and neutralizing (MN) antibody titer rises were 17.2 and 30.8 in the primed group, compared to 2.3 and 8.0 in the control group, respectively. The majority (79%) of the primed individuals achieved seroprotective MN antibody titers at 7 days after the first dose of the IIV. All LAIV-primed volunteers had MN titers ≥ 1:40 by Day 28 after one dose of IIV, whereas only 58% subjects from the naïve control group developed similar immune responses at this time point. The second A(H5N1) IIV dose did not increase the immune response in the LAIV-primed group, whereas 2 doses of IIV were required for naïve volunteers to develop significant immune responses. These findings were of special significance since Russian-based LAIV technology has been licensed to WHO, through whom the vaccine has been provided to vaccine manufacturers in India, China and Thailand - countries particularly vulnerable to a pandemic influenza. The results of our study will be useful to inform the development of vaccination strategies in these countries in the event of a pandemic. SN - 2164-554X UR - https://www.unboundmedicine.com/medline/citation/26697973/Assessment_of_immune_responses_to_H5N1_inactivated_influenza_vaccine_among_individuals_previously_primed_with_H5N2_live_attenuated_influenza_vaccine_ L2 - https://www.tandfonline.com/doi/full/10.1080/21645515.2015.1069931 DB - PRIME DP - Unbound Medicine ER -